t
| Date | 14 Sept 2023 |
| Time | 07:00:04 |
| Category | Miscellaneous |
| ID | 3786M |
14 September 2023
Scancell Holdings plc
("Scancell" or the "Company")
Scancell to present three posters at the Seventh International Cancer Immunotherapy Conference
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces it will present three posters at the Seventh International Cancer Immunotherapy Conference, jointly organised by the American Association for Cancer Research, the European Network for Cancer Immunotherapy and the Cancer Research Institute and taking place on 20-23 September 2023 in Milan, Italy.
Prof Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of Scancell, commented: "We look forward to presenting at such a prestigious meeting and sharing data on our preclinical programmes with the scientific community. As previously disclosed in a recent business update, we continue to make great progress in the clinic with our two lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1 currently in Phase 1/2 clinical trials as well as leveraging the value of our antibody platform to generate revenue through high value licence agreements.
"Showcasing the potential of our technology platforms to generate further pipeline assets with high value partnering opportunities, we will be presenting encouraging data on both the Moditope® and GlyMab® platforms. Data on antibody candidates derived from the GlyMab® platform illustrate the potential of these assets as chimeric antigen receptor T cell (CAR-T) therapies and could lead to out licensing opportunities with cell therapy companies. Furthermore, we will be presenting data bolstering the potential of Modi-2 as a solid tumour cancer therapy and further characterising the response to Moditope® peptides in preclinical studies."
The title, timing and location of the poster presentation are as follows:
Poster 1
|
Poster presentation title |
Anti-sialyl-di-lewisa CAR T cells for effective anti-tumour therapy |
|
Authors |
Iniobong Charles, Katherine Cook, Bubacarr Kaira, Gaëlle Cane, Anne Skinner, Alissa Wright, Mireille Vankemmelbeke, Rachael Metheringham, Victoria Brentville and Lindy Durrant |
|
Session title |
Poster Session A |
|
Session date and time |
12.30 - 14.00 CET, 21st September, 2023 |
|
Location |
Poster Board number P232 |
Poster 2
|
Poster presentation title |
Vaccination stimulating post-translational modification specific Th1 responses repolarises the tumour environment to reduce suppressive LAP expressing T cells |
|
Authors |
Suha Atabani, Katherine Cook, Peter Symonds, Ian Daniels, Ruhul Choudhury, Alissa Wright, Anne Skinner, Victoria Brentville and Lindy Durrant |
|
Session title |
Poster Session A |
|
Session date and time |
12.30 - 14.00 CET, 21st September, 2023 |
|
Location |
Poster Board number P230 |
Poster 3
|
Poster presentation title |
Modi-2, a vaccine targeting homocitrullinated self-epitopes, stimulates potent CD4-mediated anti-tumour responses as a therapy for solid cancers |
|
Authors |
Abdullah Al-Omari, Katherine Cook, Peter Symonds, Anne Skinner, Yaling Zhu, Vince Coble, Nazim Uddin, Priscilla Ranglani, Adrian Parry, Sally Adams, Geoffrey Lynn, Lindy Durrant and Victoria Brentville |
|
Session title |
Poster Session B |
|
Session date and time |
12.45 - 14.00 CET, 22nd September, 2023 |
|
Location |
Poster Board number P217 |
Copies of the poster will be available on Scancell's website following the conference at: https://www.scancell.co.uk/vaccine-publications
|
For further information, please contact: |
|
|
|
|
|
Scancell Holdings plc |
+44 (0) 20 3727 1000 |
|
Dr Jean-Michel Cosséry, Non-Executive Chairman |
|
|
Professor Lindy Durrant, CEO |
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) |
+44 (0) 20 7710 7600 |
|
Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking) |
|
|
Nick Adams/Nick Harland (Corporate Broking) |
|
|
|
|
|
Panmure Gordon (UK) Limited (Joint Broker) |
+44 (0) 20 7886 2500 |
|
Freddy Crossley/Emma Earl (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking) |
|
|
|
|
|
Consilium Strategic Communications |
Tel.: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott/Matthew Neal/Chris Welsh |
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/